# A Double-blind, Escalating Dose, Randomized, Placebo-controlled Study Assessing PK, Safety, Tolerability in Non-ambulant DMD Subjects

> **NCT01128855** · PHASE1 · COMPLETED · sponsor: **GlaxoSmithKline** · enrollment: 20 (actual)

## Conditions studied

- Muscular Dystrophies

## Interventions

- **DRUG:** 3 mg/kg GSK2402968
- **DRUG:** 6 mg/kg GSK2402968
- **DRUG:** 9 mg/kg GSK2402968
- **DRUG:** 12 mg/kg GSK2402968
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT01128855
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-07-12
- **Primary completion:** 2011-10-25
- **Final completion:** 2011-10-25
- **Target enrollment:** 20 (ACTUAL)
- **Last updated:** 2017-07-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01128855

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01128855, "A Double-blind, Escalating Dose, Randomized, Placebo-controlled Study Assessing PK, Safety, Tolerability in Non-ambulant DMD Subjects". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT01128855. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*